Review
Open access
Sep 2026
Molecular engineering and clinical translation of T cell engaging bispecific antibodies in cancer therapy
This review consolidates recent developments in CD3-engaging bispecific antibody engineering, including format optimization, affinity modulation, selectivity enhancement, and half-life prolongation, as well as clinical applications in hematologic and solid malignancies.
Ali Najafyar, Z. Hajihassan, W. Ibrahim
· Discover Oncology · 0 citations